openPR Logo
Press release

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1), H1, 2017, Pharmaceutical Pipeline Research Report

06-29-2017 05:20 PM CET | Health & Medicine

Press release from: Market Research Provider - MRH

Market Research Hub

Market Research Hub

Market Research Hub (MRH) has added a new report titled “Proto Oncogene Tyrosine Protein Kinase ROS, Pharmaceutical Pipeline Research Report” to its vast data repository. Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196622

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Discovery stages are 2, 2, 1 and 1 respectively. Report covers products from therapy areas Oncology which include indications Bile Duct Cancer (Cholangiocarcinoma), Neuroblastoma, Non-Small Cell Lung Cancer, Solid Tumor, Anaplastic Large Cell Lymphoma (ALCL), Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Neuroendocrine Tumors, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Brain Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Prostate Cancer, Renal Cell Carcinoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas and Uveal Melanoma.

The latest report Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2017, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope:
- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- The report reviews Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase ROS (Proto-Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/proto-oncogene-tyrosine-protein-kinase-ros-proto-oncogene-c-ros-1-or-receptor-tyrosine-kinase-c-ros-oncogene-1-or-c-ros-receptor-tyrosine-kinase-or-ros1-or-ec-27101-pipeline-review-h1-2017-report.html

Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1196622

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Read More Industry News @ https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1), H1, 2017, Pharmaceutical Pipeline Research Report here

News-ID: 601739 • Views: 265

More Releases from Market Research Provider - MRH

Global Sports Accessories Market Status & Growth Analysis Forecasted till 2022
Market Research Hub (MRH) has included a new report titled “Global Sports Accessories Market Research Report 2017”, to its huge database. This research study includes information about the regional production along with revenue and market share. The report further updates that the sports market on the global level would acquire a rise at a positive CAGR during the period 2017-2022, which is surely a major boost for the concerned sector.
Global Film Release Liners Market to Rise at an Impressive Rate during the Forec …
The demand for film release liners is greatly influenced by the advancements in the packaging industry. The increased preference for modern and latest packaging all across the world, coupled with the increasing investments in the pharmaceuticals and the food and beverages industries, is expected to drive the demand in the global market for film release liners over the coming years. A new market report with a title “Global Film Release
Global Coated Graphite Market Status, Trends & Future Outlook until 2022
The latest research report added to the vast database of Market Research Hub (MRH). The study is titled “Global Coated Graphite Market Research Report 2017”, which includes information about the regional segmentation on the basis of factors such as production, consumption, revenue, and market share. It is also mentioned that the market would soon acquire growth at a double-digit CAGR between 2017 and 2022. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217172 Geographically, this
Global High Voltage Measuring Equipments Market Status & Future Forecast during …
The most common use of high voltage measuring equipment is related to the field of power transmission. Also, the need for these equipment are rising due to demand from the industrial sector as well. Hence, to study the market for high voltage measuring equipment, Market Research Hub (MRH) has added a new study to its wide database. This research study is titled “Global High Voltage Measuring Equipments Market Research Report

All 5 Releases


More Releases for Oncogene

Myc Proto Oncogene Protein Market 2019 and Key Players: Peptomyc SL, Phylogica L …
Global Myc Proto Oncogene Protein Market Report provides manufacturers, regional analysis, prediction, segmentation by applications and type and also the exact procedure of the whole industry. Global Myc Proto Oncogene Protein market report supplies an in-depth study with upcoming and present opportunities to describe the future investments in the industry. International Myc Proto Oncogene Protein market research report offers an analysis of product type, categories, end-users, and industry chain arrangement prediction
Global Proto-Oncogene Market and Clinical Pipeline Insight 2024 Report
“Global Proto Oncogene Market and Clinical Pipeline Insight 2024” report highlights: * Oncogenes as Therapeutic Targets for Treatment * Market Analysis of Proto Oncogene Therapeutic Drugs * Dosage and Price Analysis of Drugs * Patent and Approval Year Insight * Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication and Phase * Marketed Proto Oncogene Inhibitors Clinical Insight by Company and Indication Download Report Sample Weblink: https://www.kuickresearch.com/report-global-proto-oncogene-market-and-clinical-pipeline-insight-2024.php For Report Sample Contact: neeraj@kuickresearch.com Table of Contents 1. Introduction
RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 …
ReportsWorldwide has announced the addition of a new report title RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
In Depth Research on Oncogene Inhibitors Market & Pipeline Insight 2015
" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight: * Global Oncogene Inhibitors Market Overview * Oncogene Inhibitors Pipeline by Company, Indication & Phase * Oncogene Inhibitors Pipeline: 185 Drugs * Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs * Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs * Proto Oncogene Protein c-akt Inhibitors: 39 Drugs * Marketed Oncogene Inhibitors: 22 Drugs * Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs For Report Sample Contact: neeraj@kuickresearch.com
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H2 2017”, targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages
Oncogene Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2015
Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and